Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 6/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10027235 | 0.92 | MAPT (0.36) | LMNAMAPT | |
| SCHEMBL10027186 | 0.90 | CHEK1 (0.32) | MAPTAURKA | |
| SCHEMBL10027291 | 0.86 | MAPT (0.36) | LMNAMAPTTP53DHFRAURKA | |
| SCHEMBL19361118 | 0.86 | AURKA (0.36) | LMNAMAPTTP53DHFRAURKA | |
| SCHEMBL10027311 | 0.85 | MAPT (0.36) | LMNAMAPTTP53DHFRAURKA | |
| SCHEMBL17802274 | 0.81 | CHEK1 (0.51) | LMNAMAPTTP53DHFRAURKA | |
| SCHEMBL17808748 | 0.81 | LMNA (0.32) | LMNAMAPTTP53DHFR | |
| SCHEMBL21577493 | 0.81 | ALDH1A1 (0.35) | LMNAMAPTHSD17B10 | |
| SCHEMBL17808764 | 0.80 | PDE3B (0.36) | — | |
| SCHEMBL17808794 | 0.80 | JAK2 (0.39) | LMNAMAPTTP53AURKAPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163018-B2 | Method of treatment of age-related macular degeneration (AMD) | PRANA BIOTECHNOLOGY INC. (AU) | 2015-10-20 | — | — | US | disclosed |
| US-9163018-B2 | Method of treatment of age-related macular degeneration (AMD) | PRANA BIOTECHNOLOGY INC. (AU) | 2015-10-20 | — | — | US | disclosed |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-03-27 | — | — | US | disclosed |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-03-27 | — | — | US | disclosed |
| EP-2044026-B1 | METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR | PRANA BIOTECHNOLOGY LTD (AU) | 2014-03-26 | — | — | EP | disclosed |
| EP-2514423-A2 | Method of treatment of age-related macular degeneration (AMD) | Prana Biotechnology Ltd (AU) | 2012-10-24 | — | — | EP | disclosed |
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2011-03-24 | — | — | US | disclosed |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2011-03-24 | — | — | US | disclosed |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-10 | — | — | US | disclosed |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-10 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | MGMT, DHFR, IDH2 | LMNA 2250/4885MAPT 1067/4885TP53 10/4885 |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | LMNA 400/4885MAPT 2308/4885TP53 3870/4885 |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | LMNA 400/4885MAPT 2308/4885TP53 3870/4885 |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | LMNA 400/4885MAPT 2308/4885TP53 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.